Review Article | Published:

Targeting the cancer epigenome for therapy

Nature Reviews Genetics volume 17, pages 630641 (2016) | Download Citation


Next-generation sequencing has revealed that more than 50% of human cancers harbour mutations in enzymes that are involved in chromatin organization. Tumour cells not only are activated by genetic and epigenetic alterations, but also routinely use epigenetic processes to ensure their escape from chemotherapy and host immune surveillance. Hence, a growing emphasis of recent drug discovery efforts has been on targeting the epigenome, including DNA methylation and histone modifications, with several new drugs being tested and some already approved by the US Food and Drug Administration (FDA). The future will see the increasing success of combining epigenetic drugs with other therapies. As epigenetic drugs target the epigenome as a whole, these true 'genomic medicines' lessen the need for precision approaches to individualized therapies.

Key points

  • Tumour cells often have mutations in genes that encode regulators of the epigenome.

  • Cancers use both genetic and epigenetic alterations to evolve and develop resistance to immune surveillance and chemotherapy.

  • DNA methylation inhibitors are the standard of care for certain haematological malignancies and form the backbones of many trials in solid tumours.

  • Several new drugs that target histone modifications are being tested in clinical trials.

  • DNA methylation inhibitors activate not only abnormally silenced genes, but also cancer testis antigens (CTAs) and endogenous retroviruses (ERVs). Activation of CTAs and ERVs may increase the visibility of the tumour to the immune system and increase the efficacy of immunotherapy.

  • Therapies that combine epigenetic drugs and standard chemotherapy will become important clinical tools in the future.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    & Histone core modifications regulating nucleosome structure and dynamics. Nat. Rev. Mol. Cell Biol. 15, 703–708 (2014).

  2. 2.

    Roadmap Epigenomics Consortium et al. Integrative analysis of 111 reference human epigenomes. Nature 518, 317–330 (2015).

  3. 3.

    et al. A blueprint for an international cancer epigenome consortium. A report from the AACR Cancer Epigenome Task Force. Cancer Res. 72, 6319–6324 (2012).

  4. 4.

    Cancer Genome Atlas Research Network et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat. Genet. 45, 1113–1120 (2013).

  5. 5.

    et al. DNA methylome analysis in Burkitt and follicular lymphomas identifies differentially methylated regions linked to somatic mutation and transcriptional control. Nat. Genet. 47, 1316–1325 (2015).

  6. 6.

    & Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell 22, 9–20 (2012).

  7. 7.

    , & SWI/SNF chromatin remodeling complexes and cancer. Am. J. Med. Genet. C. Semin. Med. Genet. 166C, 350–366 (2014).

  8. 8.

    et al. Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. Nature 506, 445–450 (2014).

  9. 9.

    & Mammalian SWI/SNF chromatin remodeling complexes and cancer: mechanistic insights gained from human genomics. Sci. Adv. 1, e1500447 (2015). This is an excellent review of chromatin-remodelling complexes.

  10. 10.

    et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 483, 474–478 (2012).

  11. 11.

    et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483, 479–483 (2012).

  12. 12.

    et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18, 553–567 (2010).

  13. 13.

    et al. Insulator dysfunction and oncogene activation in IDH mutant gliomas. Nature 529, 110–114 (2016).

  14. 14.

    et al. TET2 mutations affect non-CpG island DNA methylation at enhancers and transcription factor binding sites in chronic myelomonocytic leukemia. Cancer Res. 75, 2833–2843 (2015).

  15. 15.

    et al. The R882H DNMT3A mutation associated with AML dominantly inhibits wild-type DNMT3A by blocking its ability to form active tetramers. Cancer Cell 25, 442–454 (2014).

  16. 16.

    et al. Histone H3K36 mutations promote sarcomagenesis through altered histone methylation landscape. Science 352, 844–849 (2016).

  17. 17.

    et al. Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas. Cancer Cell 24, 660–672 (2013).

  18. 18.

    & Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat. Genet. 33, 245–254 (2003).

  19. 19.

    et al. A zebrafish melanoma model reveals emergence of neural crest identity during melanoma initiation. Science 351, aad2197 (2016). A breakthrough paper demonstrating the importance of epigenetic states on the expression of oncogenic phenotype.

  20. 20.

    et al. Atypical teratoid/rhabdoid tumors are comprised of three epigenetic subgroups with distinct enhancer landscapes. Cancer Cell 29, 379–393 (2016).

  21. 21.

    et al. DNA methylation dynamics during B cell maturation underlie a continuum of disease phenotypes in chronic lymphocytic leukemia. Nat. Genet. 48, 253–264 (2016).

  22. 22.

    Environmental exposures and mutational patterns of cancer genomes. Genome Med. 2, 54 (2010).

  23. 23.

    , , & 5-methylcytosine as an endogenous mutagen in the human LDL receptor and p53 genes. Science 249, 1288–1290 (1990).

  24. 24.

    et al. Changes in DNA methylation patterns in subjects exposed to low-dose benzene. Cancer Res. 67, 876–880 (2007).

  25. 25.

    et al. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat. Genet. 7, 536–540 (1994).

  26. 26.

    DNA methylation age of human tissues and cell types. Genome Biol. 14, R115 (2013); erratum 16, 96 (2015).

  27. 27.

    et al. Vitamin C induces Tet-dependent DNA demethylation and a blastocyst-like state in ES cells. Nature 500, 222–226 (2013). A key paper emphasizing the important role of vitamin C as a cofactor for the TET enzymes.

  28. 28.

    et al. Mutation in TET2 in myeloid cancers. N. Engl. J. Med. 360, 2289–2301 (2009).

  29. 29.

    , , , & Regulation of DNA-damage responses and cell-cycle progression by the chromatin remodelling factor CHD4. EMBO J. 29, 3130–3139 (2010).

  30. 30.

    et al. The NuRD chromatin-remodeling complex regulates signaling and repair of DNA damage. J. Cell Biol. 190, 741–749 (2010).

  31. 31.

    et al. A chromatin localization screen reveals poly (ADP ribose)-regulated recruitment of the repressive polycomb and NuRD complexes to sites of DNA damage. Proc. Natl Acad. Sci. USA 107, 18475–18480 (2010).

  32. 32.

    , & Double strand breaks can initiate gene silencing and SIRT1-dependent onset of DNA methylation in an exogenous promoter CpG island. PLoS Genet. 4, e1000155 (2008).

  33. 33.

    et al. Oxidative damage targets complexes containing DNA methyltransferases, SIRT1, and Polycomb members to promoter CpG Islands. Cancer Cell 20, 606–619 (2011).

  34. 34.

    et al. BET and HDAC inhibitors induce similar genes and biological effects and synergize to kill in Myc-induced murine lymphoma. Proc. Natl Acad. Sci. USA 111, E2721–E2730 (2014).

  35. 35.

    et al. Gene body methylation can alter gene expression and is a therapeutic target in cancer. Cancer Cell 26, 577–590 (2014).

  36. 36.

    & Cellular differentiation, cytidine analogs and DNA methylation. Cell 20, 85–93 (1980).

  37. 37.

    et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 103, 1635–1640 (2004).

  38. 38.

    et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 10, 223–232 (2009). A key paper demonstrating the efficacy of DNMTi in the treatment of MDS.

  39. 39.

    et al. Decitabine improves progression-free survival in older high-risk MDS patients with multiple autosomal monosomies: results of a subgroup analysis of the randomized phase III study 06011 of the EORTC Leukemia Cooperative Group and German MDS Study Group. Ann. Hematol. 95, 191–199 (2016).

  40. 40.

    , , , & Induction of hypomethylation and molecular response after decitabine therapy in patients with chronic myelomonocytic leukemia. Blood 111, 2382–2384 (2008).

  41. 41.

    et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 21, 430–446 (2012).

  42. 42.

    et al. Mechanisms of resistance to decitabine in the myelodysplastic syndrome. PLoS ONE 6, e23372 (2011).

  43. 43.

    et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J. Clin. Oncol. 29, 3322–3327 (2011).

  44. 44.

    et al. Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. Clin. Cancer Res. 15, 3881–3888 (2009).

  45. 45.

    et al. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. Lancet Oncol. 16, 1099–1110 (2015). This paper helped in the development of guadecitabine, the first new DNMT inhibitor in four decades.

  46. 46.

    et al. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc. Natl Acad. Sci. USA 95, 3003–3007 (1998).

  47. 47.

    & Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat. Rev. Drug Discov. 13, 673–691 (2014).

  48. 48.

    et al. Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 15, 1195–1206 (2014).

  49. 49.

    , & Histone deacetylase inhibitors as anti-neoplastic agents. Cancer Lett. 280, 192–200 (2009).

  50. 50.

    et al. Selective inhibition of BET bromodomains. Nature 468, 1067–1073 (2010).

  51. 51.

    et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146, 904–917 (2011).

  52. 52.

    et al. Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 153, 320–334 (2013).

  53. 53.

    et al. Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet. 42, 181–185 (2010).

  54. 54.

    et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492, 108–112 (2012).

  55. 55.

    IDH2 inhibition in AML: finally progress? Best Pract. Res. Clin. Haematol. 28, 112–115 (2015).

  56. 56.

    et al. Extreme vulnerability of IDH1 mutant cancers to NAD+ depletion. Cancer Cell 28, 773–784 (2015).

  57. 57.

    et al. An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 340, 626–630 (2013).

  58. 58.

    et al. DNA methylation does not stably lock gene expression but instead serves as a molecular mark for gene silencing memory. Cancer Res. 72, 1170–1181 (2012).

  59. 59.

    et al. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT inhibitor decitabine. Oncotarget 4, 1729–1736 (2013).

  60. 60.

    et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 20, 53–65 (2011).

  61. 61.

    et al. A DNA hypomethylation signature predicts antitumor activity of LSD1 inhibitors in SCLC. Cancer Cell 28, 57–69 (2015).

  62. 62.

    et al. G9a, a multipotent regulator of gene expression. Epigenetics 8, 16–22 (2013).

  63. 63.

    et al. Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia. Nature 514, 513–517 (2014).

  64. 64.

    et al. Targeting calcium signaling induces epigenetic reactivation of tumor suppressor genes in cancer. Cancer Res. 76, 1494–1505 (2016).

  65. 65.

    et al. Effect of cytarabine and decitabine in combination in human leukemic cell lines. Clin. Cancer Res. 13, 4225–4232 (2007).

  66. 66.

    et al. DNA methylation changes after 5-aza-2′-deoxycytidine therapy in patients with leukemia. Cancer Res. 66, 5495–5503 (2006).

  67. 67.

    et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109, 52–57 (2007).

  68. 68.

    et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment. Blood 100, 2957–2964 (2002). This paper definitively showed the demethylation of a tumour suppressor gene in patients.

  69. 69.

    et al. LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors. Epigenetics 4, 176–184 (2009).

  70. 70.

    et al. Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup study. Br. J. Haematol. 172, 384–391 (2015).

  71. 71.

    et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J. Clin. Oncol. 28, 605–613 (2010).

  72. 72.

    et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood 114, 2764–2773 (2009).

  73. 73.

    et al. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J. Clin. Oncol. 18, 956–962 (2000).

  74. 74.

    & Targeting DNA methylation. Clin. Cancer Res. 15, 3938–3946 (2009).

  75. 75.

    Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N. Engl. J. Med. 368, 2059–2074 (2013).

  76. 76.

    et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood 124, 2705–2712 (2014).

  77. 77.

    et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia 25, 1147–1152 (2011).

  78. 78.

    et al. Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. Leukemia 28, 78–87 (2014).

  79. 79.

    , & Inhibition of DNA methylation by 5-aza-2′-deoxycytidine suppresses the growth of human tumor cell lines. Cancer Res. 58, 95–101 (1998).

  80. 80.

    et al. Silenced tumor suppressor genes reactivated by DNA demethylation do not return to a fully euchromatic chromatin state. Cancer Res. 66, 3541–3549 (2006).

  81. 81.

    et al. Role of nucleosomal occupancy in the epigenetic silencing of the MLH1 CpG island. Cancer Cell 12, 432–444 (2007).

  82. 82.

    et al. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 9, 435–443 (2006).

  83. 83.

    in Stem Book (ed. Girard, L.) (Harvard Stem Cell Insitute, 2009).

  84. 84.

    & A decade of exploring the cancer epigenome — biological and translational implications. Nat. Rev. Cancer 11, 726–734 (2011).

  85. 85.

    et al. Stem-cell ageing modified by the cyclin-dependent kinase inhibitor p16INK4a. Nature 443, 421–426 (2006).

  86. 86.

    et al. Long-term haematopoietic reconstitution by Trp53−/− p16 Ink4a−/− p19Arf−/− multipotent progenitors. Nature 453, 228–232 (2008).

  87. 87.

    & The epigenomics of cancer. Cell 128, 683–692 (2007).

  88. 88.

    et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141, 69–80 (2010). A key paper demonstrating the importance of epigenetic mechanisms in drug resistance.

  89. 89.

    et al. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2′-deoxycytidine. Cancer Res. 54, 1766–1771 (1994).

  90. 90.

    & Reactivating the expression of methylation silenced genes in human cancer. Oncogene 21, 5496–5503 (2002).

  91. 91.

    et al. Inhibition of DNA methyltransferase stimulates the expression of signal transducer and activator of transcription 1, 2, and 3 genes in colon tumor cells. Proc. Natl Acad. Sci. USA 96, 14007–14012 (1999).

  92. 92.

    et al. Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell 162, 974–986 (2015).

  93. 93.

    et al. DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell 162, 961–973 (2015). References 92 and 93 were the first to link activation of ERVs to cellular response.

  94. 94.

    , & Phenotypic conversion of cultured mouse embryo cells by aza pyrimidine nucleosides. Dev. Biol. 66, 57–71 (1978).

  95. 95.

    & The Death of Cancer (Sarah Crighton Books, 2015).

  96. 96.

    et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031–1037 (2001).

  97. 97.

    et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 20, 5054–5058 (2001).

  98. 98.

    Cancer Genome Atlas Network. Genomic classification of cutaneous melanoma. Cell 161, 1681–1696 (2015).

  99. 99.

    Current status of targeted therapy in non-small cell lung cancer. Drugs Today (Barc.) 50, 503–525 (2014).

  100. 100.

    & Mutant BRAF melanomas — dependence and resistance. Cancer Cell 19, 11–15 (2011).

  101. 101.

    , & Epigenetic therapeutics: a new weapon in the war against cancer. Annu. Rev. Med. 67, 73–89 (2016).

  102. 102.

    , , & The future of epigenetic therapy in solid tumours — lessons from the past. Nat. Rev. Clin. Oncol. 10, 256–266 (2013).

  103. 103.

    , , & Epigenetics in human disease and prospects for epigenetic therapy. Nature 429, 457–463 (2004).

  104. 104.

    , , , & Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Genet. 21, 103–107 (1999). An early paper demonstrating the feasibility of combination therapies with epigenetic drugs.

  105. 105.

    & Methylation-induced repression — belts, braces, and chromatin. Cell 99, 451–454 (1999).

  106. 106.

    , , , & DNA methylation models histone acetylation. Nature 394, 842 (1998).

  107. 107.

    et al. The NuRD complex cooperates with DNMTs to maintain silencing of key colorectal tumor suppressor genes. Oncogene 33, 2157–2168 (2014).

  108. 108.

    et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat. Genet. 31, 141–149 (2002).

  109. 109.

    et al. Chemical phylogenetics of histone deacetylases. Nat. Chem. Biol. 6, 238–243 (2010).

  110. 110.

    et al. HDAC inhibitors act with 5-aza-2′-deoxycytidine to inhibit cell proliferation by suppressing removal of incorporated abases in lung cancer cells. PLoS ONE 3, e2445 (2008).

  111. 111.

    , , & Combinations of DNA methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung cancer cells: correlation of resistance with IFN-stimulated gene expression. Mol. Cancer Ther. 9, 2309–2321 (2010).

  112. 112.

    , , & DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res. 61, 1327–1333 (2001).

  113. 113.

    & The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curr. Med. Chem. Anticancer Agents 3, 187–199 (2003).

  114. 114.

    et al. Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. J. Clin. Oncol. 32, 1242–1248 (2014).

  115. 115.

    et al. Phase I/II study of MGCD0103, an oral isotype-selective histone deacetylase (HDAC) inhibitor, in combination with 5-azacitidine in higher-risk myelodysplastic syndrome (MDS) and acute myelogenous leukemia (AML). Blood Abstr. 110, 444 (2007).

  116. 116.

    et al. A phase I trial of the epigenetic modulators vorinostat, in combination with azacitidine (azaC) in patients with the myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML): a study of the New York Cancer Consortium. Blood Abstr. 112, 3656 (2008). This article underlines the potential for combination therapies in patients.

  117. 117.

    et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov. 1, 598–607 (2011). This paper presents preliminary evidence for the concept of 'priming' patients with DNMTi before immune checkpoint therapy.

  118. 118.

    et al. Alterations of immune response of non-small cell lung cancer with azacytidine. Oncotarget 4, 2067–2079 (2013).

  119. 119.

    , , , & Carboplatin with decitabine therapy, in recurrent platinum resistant ovarian cancer, alters circulating miRNAs concentrations: a pilot study. PLoS ONE 10, e0141279 (2015).

  120. 120.

    et al. A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer. Cancer 116, 4043–4053 (2010).

  121. 121.

    et al. The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer. Clin. Cancer Res. 20, 6504–6516 (2014).

  122. 122.

    et al. Decitabine reactivated pathways in platinum resistant ovarian cancer. Oncotarget 5, 3579–3589 (2014).

  123. 123.

    et al. Epigenetic resensitization to platinum in ovarian cancer. Cancer Res. 72, 2197–2205 (2012). A key trial demonstrating the potential for DNMTi to reverse drug resistance in the clinic.

  124. 124.

    & Epigenetic therapies for chemoresensitization of epithelial ovarian cancer. Gynecol. Oncol. 116, 195–201 (2010).

  125. 125.

    et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455–2465 (2012).

  126. 126.

    & Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161, 205–214 (2015).

  127. 127.

    , & Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27, 450–461 (2015).

  128. 128.

    , & Mechanisms of immune evasion by tumors. Adv. Immunol. 90, 51–81 (2006).

  129. 129.

    , & Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331, 1565–1570 (2011).

  130. 130.

    , & Augmenting antitumor immune responses with epigenetic modifying agents. Front. Immunol. 6, 29 (2015).

  131. 131.

    A potential role for epigenetic modulatory drugs in the enhancement of cancer/germ-line antigen vaccine efficacy. Epigenetics 1, 116–120 (2006).

  132. 132.

    , , & Combining epigenetic and immunotherapy to combat cancer. Cancer Res. 76, 1683–1689 (2016).

  133. 133.

    Epigenetic modulators and the new immunotherapies. N. Engl. J. Med. 374, 684–686 (2016).

  134. 134.

    et al. Loss of LSD1 (lysine-specific demethylase 1) suppresses growth and alters gene expression of human colon cancer cells in a p53- and DNMT1 (DNA methyltransferase 1)-independent manner. Biochem. J. 449, 459–468 (2013).

  135. 135.

    et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119, 941–953 (2004).

  136. 136.

    et al. Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy. Nature 527, 249–253 (2015).

  137. 137.

    New targets for hematologic malignancies. Clin. Adv. Hematol. Oncol. 11, 375–376 (2013).

  138. 138.

    & Cancer epigenetics: from mechanism to therapy. Cell 150, 12–27 (2012).

  139. 139.

    et al. Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells. Mol. Cancer Ther. 13, 1142–1154 (2014).

  140. 140.

    , , , & Epigenetics (Cold Spring Harbor Laboratory Press, 2015).

  141. 141.

    Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat. Rev. Genet. 13, 484–492 (2012).

  142. 142.

    et al. Regions of focal DNA hypermethylation and long-range hypomethylation in colorectal cancer coincide with nuclear lamina-associated domains. Nat. Genet. 44, 40–46 (2012). This paper defines the distribution of cytosine methylation in uncultured human cancers.

Download references


Research funding was provided by the Van Andel Research Institute–Stand Up To Cancer (SU2C) Epigenetics Dream Team, of which the authors are members. SU2C is a programme of the Entertainment Industry Foundation (EIF), administered by the American Association for Cancer Research (AACR). P.A.J. is supported by the US National Cancer Institute (RO1 CA082422). J.-P.J.I. is supported by the US National Institutes of Health (NIH) (CA158112 and CA100632) and by a grant from the Ellison Medical Foundation. He is also an American Cancer Society Clinical Research Professor supported by a generous gift from the F.M. Kirby Foundation. S.B. receives support from the NIH (R01 CA170550), the EIF Jim Toth Sr. Breakthrough Lung Cancer Research Award, the Rising Tide Foundation and SU2C (SU2C-AACR-CT0109).

Author information


  1. Van Andel Research Institute, Grand Rapids, Michigan 49503, USA.

    • Peter A. Jones
    •  & Stephen Baylin
  2. Fels Institute for Cancer Research, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania 19140, USA.

    • Jean-Pierre J. Issa
  3. Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21287, USA.

    • Stephen Baylin


  1. Search for Peter A. Jones in:

  2. Search for Jean-Pierre J. Issa in:

  3. Search for Stephen Baylin in:

Competing interests

P.A.J. is a paid consultant for Zymo Corporation. S.B. has consulted for Celgene Corporation, Astex Pharmaceuticals, Chugai Pharmaceuticals, Merck–Pfizer and Merck & Co. regarding some of the work mentioned. J.-P.J.I. is a consultant for and has received research support from Astex Pharmaceuticals.

Corresponding author

Correspondence to Peter A. Jones.



Enzymes that apply covalent modifications, such as methyl or acetyl groups, to specific amino acids on histones.


Proteins that can recognize specific modifications on histones at defined positions in the protein backbone.


The reversibility of epigenetic marks on DNA and proteins.


Enzymes that can remove specific modifications at defined sites on DNA or histones.

TET family

The ten-eleven translocation family of α-ketoglutarate-dependent dioxygenases catalyse the oxidation of 5-methlcytosine (5mC) to 5-hydroxymethylcytosine (5hmC) and further products. Genes encoding these enzymes are frequently mutated in human cancers.


A gene in which the activation or deactivation of expression is causally related to the establishment of the malignant state.

Genomic medicines

Drugs that have wide-ranging effects on the epigenome.

Precision medicine

The use of drugs to target specific abnormalities identified in a patient.

Synthetic lethality

A relationship between two genes in which the combined inactivation of the genes results in cell death, whereas the inactivation of either gene alone has no effect. It can also refer to a gene whose perturbation only results in cell death in the presence of a particular cellular feature (for example, a mutation).


(Long interspersed nuclear elements). Highly repetitious elements that make up a considerable portion of the human genome; their methylation status can be used as a surrogate for overall genomic methylation.

Alu elements

Interspersed DNA sequences of about 300bp that belong to the short interspersed element (SINE) family and are found in the genome of primates.

Frontline therapy

The use of a drug early in treatment before other drugs have been used.

CCCTC-binding factor sites

(CTCF sites). Binding sites for the CTCF transcription factor, which is involved in transcriptional activation, insulator activity and regulation of chromatin architecture.

Cancer testis antigens

(CTAs). A group of proteins expressed during male germ cell development, which are silenced in normal cells and may become re-expressed ectopically in cancers. Many are highly immunogenic.


The use of a single drug to treat a malignancy.

Immune checkpoint therapy

The use of antibodies that target regulatory pathways in T cells to enhance antitumour immune response.

About this article

Publication history



Further reading